Inactive Instrument

Renovacor, Inc.

Equities

RCOR

US75989E1064

Biotechnology & Medical Research

Renovacor, Inc. Appoints Kumar Dhanasekharan as Senior Vice President of Technical Operations

October 04, 2021 at 04:05 pm EDT

Renovacor, Inc. announced the appointment of Kumar Dhanasekharan, Ph.D., as Senior Vice President of Technical Operations. Prior to joining Renovacor, Dr. Dhanasekharan served as Vice President of Technical Operations at SwanBio Therapeutics.

Latest news about Renovacor, Inc.

Renovacor, Inc.(NYSEAM:RCOR) dropped from S&P TMI Index	22-12-01	CI
Rocket Pharmaceuticals, Inc. completed the acquisition of Renovacor, Inc. from RTW Investments, LP, Chardan Investments 2, LLC and others,	22-11-30	CI
Renovacor, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-10	CI
North American Morning Briefing : Stocks to Steady -2-	22-09-22	DJ
Baird Downgrades Renovacor to Neutral From Outperform, Adjusts Price Target to $2.75 From $9	22-09-21	MT
BTIG Downgrades Renovacor to Neutral From Buy	22-09-21	MT
Sector Update: Health Care Stocks Struggle on Tuesday	22-09-20	MT
Ladenburg Thalmann Downgrades Renovacor to Neutral From Buy, Adjusts Price Target to $2.60 From $22	22-09-20	MT
Sector Update: Health Care Stocks Dropping in Afternoon Trade	22-09-20	MT
Sector Update: Health Care Stocks Decline Premarket Tuesday	22-09-20	MT
Wall Street Set to Open Lower Ahead of Fed Meeting	22-09-20	MT
US Futures Lower as Investors Gird for Another Fed Rate Increase	22-09-20	MT
Transcript : Renovacor, Inc., Rocket Pharmaceuticals, Inc. - M&A Call	22-09-20
Top Premarket Gainers	22-09-20	MT
Rocket Pharmaceuticals to Acquire Renovacor in $53 Million All-Stock Deal	22-09-20	MT
Rocket Pharmaceuticals, Inc. entered into a definitive agreement to acquire Renovacor, Inc. from RTW Investments, LP, Chardan Investments 2, LLC and others for $49.1 million.	22-09-19	CI
BTIG Starts Renovacor at Buy With $8 Price Target	22-09-14	MT
Baird Initiates Renovacor at Outperform With $9 Price Target	22-09-13	MT
Renovacor, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-08	CI
Renovacor Announces Pipeline Expansion with New Research Program for Multiple Genetic Segments of Arrhythmogenic Cardiomyopathy	22-07-12	CI
Renovacor Appoints Wendy Dicicco as the Chief Financial Officer	22-06-24	CI
Renovacor Announces Executive Appointments	22-06-24	CI
Renovacor, Inc.(NYSEAM:RCOR) added to Russell Microcap Value Index	22-06-24	CI
Renovacor, Inc.(NYSEAM:RCOR) added to Russell 3000E Index	22-06-24	CI
Renovacor, Inc.(NYSEAM:RCOR) added to Russell Microcap Index	22-06-24	CI

Chart Renovacor, Inc.

Duration

Period

More charts

Company Profile

Renovacor, Inc. is a preclinical-stage gene therapy company. The Company is engaged in developing a pipeline of adeno-associated virus (AAV)-based gene therapies for Bcl2-associated athanogene 3 (BAG3) gene mutation-associated diseases in areas of unmet medical need. The Company's therapeutic focuses on cardiovascular disease, with a lead program in BAG3 mutation-associated dilated cardiomyopathy. Its lead product candidate, REN-001, is an AAV9-based gene therapy designed to treat BAG3-associated dilated cardiomyopathy (DCM). The Company is also conducting preclinical studies exploring the ability of a BAG3 gene therapy to treat patients suffering from DCM caused by BAG3 haploinsufficiency. The Company's preclinical strategy is to advance earlier stage research programs of its BAG3 gene therapy. Its research and discovery programs include BAG3- mediated diseases associated with the cardiovascular system and the central nervous system.

Sector

Biotechnology & Medical Research

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
MODERNA, INC.	+29.77%	49.46B
IQVIA HOLDINGS INC.	+1.00%	42.58B
LONZA GROUP AG	+49.79%	42.49B
CELLTRION, INC.	-5.26%	29.09B
ICON PUBLIC LIMITED COMPANY	+13.68%	26.61B
ALNYLAM PHARMACEUTICALS, INC.	-22.99%	18.64B
BIO-TECHNE CORPORATION	+8.22%	13.16B
MEDPACE HOLDINGS, INC.	+32.41%	12.55B
UNITED THERAPEUTICS CORPORATION	+24.01%	12.1B

Other Biotechnology & Medical Research